| abstract |
The present invention relates to a heterocyclic sulfoximine compound represented by formula (I), and racemates, enantiomers, pharmaceutically acceptable salts or solvates thereof. Also disclosed herein are an intermediate compound for synthesizing the compound, a preparation method therefor, and a pharmaceutical composition comprising the compound and use thereof. The compound is RET, RET mutant, or RET fusion protein inhibitor, capable of treating diseases caused by abnormal activity of RET, RET mutant, or RET fusion protein, for example, tumors. |